SCHEMBL30788350

SCHEMBL30788350

C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(N)=O

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NMUR2 Q9GZQ4 6/20 0.58
▸ NMUR1 Q9HB89 6/20 0.58
▸ OPRM1 P35372 2/20 0.56
▸ OPRD1 P41143 2/20 0.56
▸ CXCR4 P61073 2/20 0.55
▸ EPHA2 P29317 2/20 0.55
▸ RAMP3 O60896 1/20 0.54
▸ CALCR P30988 1/20 0.54
▸ TFPI P10646 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753759 0.95 NMUR2 (0.62) NMUR2NMUR1OPRM1OPRD1CXCR4
SCHEMBL30788368 0.95 NMUR2 (0.58) NMUR2NMUR1OPRM1OPRD1CXCR4
SCHEMBL30788363 0.94 NMUR2 (0.59) NMUR2NMUR1OPRM1OPRD1CXCR4
SCHEMBL30788356 0.92 TFPI (0.61) NMUR2NMUR1OPRM1CXCR4TFPI
SCHEMBL30233422 0.90 C5AR1 (0.58) NMUR2NMUR1OPRM1OPRD1CXCR4
SCHEMBL30233254 0.89 OPRD1 (0.61) NMUR2NMUR1OPRM1OPRD1CALCR
SCHEMBL30788362 0.89 F2 (0.56) NMUR2NMUR1CXCR4TFPI
SCHEMBL30753756 0.89 NMUR2 (0.61) NMUR2NMUR1OPRM1OPRD1CXCR4
SCHEMBL30753761 0.88 OPRD1 (0.61) NMUR2NMUR1OPRM1OPRD1CALCR
SCHEMBL30788354 0.88 TFPI (0.55) NMUR2NMUR1OPRM1OPRD1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-05-02 — — US disclosed
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-04-18 — — US disclosed
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY GLO PHARMA, INC. 2024-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, PLIN3 NMUR2 1728/4885NMUR1 2016/4885OPRM1 4773/4885
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNB1, CHRNG, CHRNA1 NMUR2 27/4885NMUR1 22/4885OPRM1 2825/4885
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, LIPE NMUR2 2354/4885NMUR1 2738/4885OPRM1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback